Inhaled Preparation Spray Particle Size Testing: Methods, Standards, and Applications

Spray particle size testing is a critical quality attribute evaluation for orally inhaled and nasal drug products, because the aerodynamic diameter of droplets and particles directly determines where the active pharmaceutical ingredient deposits within the respiratory tract. This article explains the key measurement parameters—such as MMAD, GSD, and fine particle fraction—along with the principal test methods, including cascade impaction and laser diffraction, and the compendial standards that accredited third-party laboratories apply when testing metered dose inhalers, dry powder inhalers, nebulizers, and nasal sprays.

Technical Overview

Inhaled preparations, including pressurized metered dose inhalers (pMDIs), dry powder inhalers (DPIs), nebulized solutions and suspensions, soft mist inhalers, and nasal sprays, deliver drug substance directly to the respiratory tract. Because deposition within the airways is governed primarily by particle and droplet size, the aerodynamic particle size distribution (APSD) is universally recognized as a critical quality attribute (CQA) in quality-by-design frameworks such as ICH Q8, Q9, and Q10.

The regional deposition behavior of inhaled particles follows well-established patterns. Particles larger than approximately 5 µm in aerodynamic diameter tend to impact in the oropharynx and central airways, particles between roughly 1 µm and 5 µm sediment in the bronchial and bronchiolar regions, particles near 1–3 µm can reach the alveolar region, and particles below about 0.5 µm are largely exhaled without depositing. Consequently, controlling the spray plume and the size distribution of the emitted dose is essential for therapeutic efficacy and for minimizing local side effects such as oral candidiasis caused by oropharyngeal deposition of inhaled corticosteroids.

Two complementary measurement concepts must be distinguished. Geometric or volumetric droplet size, typically measured by laser diffraction, describes the physical dimensions of the spray droplets shortly after actuation and before propellant evaporation is complete. Aerodynamic diameter, measured by cascade impaction combined with chemical assay, describes the mass-weighted size of drug-containing particles as they actually behave in a moving airstream. Both perspectives are required for a complete characterization of an inhaled product.

Testing Samples

Pressurized Metered Dose Inhalers (pMDIs)

Solution and suspension formulations delivered from pressurized containers with hydrofluoroalkane (HFA) propellants are tested for droplet size distribution of the emitted plume, aerodynamic particle size of the residual particles after evaporation, spray pattern, and plume geometry. Both the formulation and the metering valve and actuator mouthpiece configuration influence the results.

Dry Powder Inhalers (DPIs)

Carrier-based lactose blends, pelletized or engineered particle formulations, capsule-based systems, blister multidose systems, and reservoir devices are tested for the aerodynamic size distribution of the aerosolized powder at the specified inhalation flow rate, typically defined by the device resistance (for example, 4 kPa pressure drop). Primary particle size of the bulk powder is also characterized before and after micronization.

Nebulizers, Inhalation Solutions, and Soft Mist Inhalers

Liquid preparations intended for nebulization are evaluated together with the delivery device, since droplet size depends strongly on the nebulizer mechanism, whether jet, ultrasonic, or vibrating mesh. Soft mist inhalers, which generate a slow-moving aerosol from a metered liquid, require measurement of both initial droplet size and plume behavior.

Nasal Spray Preparations

Aqueous nasal suspensions and solutions are tested for spray droplet size distribution, spray pattern, and plume geometry at defined distances from the actuator tip, because droplets larger than approximately 10 µm are retained in the nasal cavity while smaller droplets risk inhalation into the lungs.

Accessories and Reference Materials

Add-on devices such as spacers and valved holding chambers, actuator adapters, and calibration microspheres certified for particle size instrument qualification are also within the scope of professional testing laboratories.

Testing Items

Typical size-related test items for inhaled and nasal preparations include:

• Mass median aerodynamic diameter (MMAD) of the drug substance
• Geometric standard deviation (GSD) describing the width of the aerodynamic size distribution
• Fine particle dose (FPD) and fine particle fraction (FPF), commonly defined as the mass fraction below 5 µm, with additional reporting below 3 µm and 1 µm
• Mass of drug deposited on individual impactor stages and grouped stage data
• Volumetric droplet size parameters Dv10, Dv50, and Dv90 from laser diffraction
• Spray pattern parameters, including maximum diameter (Dmax), minimum diameter (Dmin), and ovality ratio
• Plume geometry parameters, including plume angle, plume width, and time to full development
• Primary particle size of bulk powders and micronized drug substance (D10, D50, D90)
• Delivered dose uniformity and emitted dose, typically tested alongside size distribution

Testing Methods

Aerodynamic Assessment by Cascade Impaction

Cascade impaction is the compendial reference method for the aerodynamic particle size distribution of inhaled products, described in USP General Chapter <601>, Ph. Eur. 2.9.18, and the corresponding monographs of the Chinese Pharmacopoeia. Instruments such as the Andersen cascade impactor operated at 28.3 L/min, the Next Generation Pharmaceutical Impactor (NGI) operated across a range of flow rates, and the Marple-Miller impactor fractionate the aerosol on calibrated stages. The drug mass collected on each stage is recovered and quantified by a validated analytical method, typically HPLC with UV detection, yielding an active-ingredient-specific size distribution from which MMAD, GSD, and fine particle fraction are calculated. Stage coating and careful control of temperature and humidity are applied to prevent particle bounce and re-entrainment.

Laser Diffraction Particle Size Analysis

Laser diffraction measures volumetric geometric size distributions of sprays, nebulized droplets, and powder dispersions in accordance with ISO 13320 and USP General Chapter <429>. For sprayed products, measurements are performed at defined distances from the actuator or nozzle tip and at defined times after actuation to capture the rapidly evaporating plume of propellant-driven products. For dry powders, dispersion conditions are adjusted to deagglomerate the sample without fracturing primary particles. Results are reported as Dv10, Dv50, and Dv90 together with the span of the distribution.

Spray Pattern and Plume Geometry Testing

For nasal sprays and pMDIs, the spatial characteristics of the spray are captured using laser-sheet illumination combined with high-speed imaging, or by impaction onto treated collection surfaces. Spray pattern (Dmax, Dmin, ovality) and plume geometry (angle, width, development time) are sensitive indicators of valve and pump performance and are required elements of in vitro bioequivalence protocols for generic products under applicable FDA and EMA guidance.

Microscopy and Dynamic Image Analysis

Optical microscopy, scanning electron microscopy, and dynamic image analysis in accordance with ISO 13322 are used to characterize particle morphology, shape, and primary particle size of powders prior to formulation, and to investigate anomalies such as agglomeration or crystal growth during stability studies.

Complementary Instrumental Techniques

Time-of-flight aerodynamic particle sizing instruments, phase-Doppler anemometry for droplet velocity and size, and inline light-obscuration counters provide supporting data during device and formulation development, particularly for high-velocity nasal sprays and soft mist products.

Applications

Spray particle size testing supports the full product lifecycle of inhaled and nasal drug products:

• Formulation development and optimization of propellant, co-solvent, surfactant, and carrier systems
• Device engineering, including actuator orifice design, nozzle geometry, and mouthpiece selection
• In vitro bioequivalence demonstrations for generic products comparing test and reference aerosol performance
• Routine batch release testing and process control in commercial manufacturing
• Long-term and accelerated stability studies under ICH Q1A storage conditions to detect changes in size distribution
• Evaluation of spacers, valved holding chambers, and dose counters used with inhalers
• Regulatory submissions, including CTD quality module documentation of APSD data
• Investigations of field complaints, batch deviations, and post-approval changes

FAQ

What is MMAD and why is it important?

MMAD is the mass median aerodynamic diameter, the particle size at which half of the total drug mass is contained in larger particles and half in smaller particles. It is the single most widely used descriptor of inhaled aerosol performance because it correlates directly with regional lung deposition and clinical effect.

What particle size reaches the lungs most effectively?

Aerodynamic diameters between approximately 1 µm and 5 µm are generally considered optimal for lower airway and alveolar deposition. Particles above 5 µm are mostly deposited in the mouth and throat, while particles below about 0.5 µm are predominantly exhaled.

What is the difference between laser diffraction and cascade impaction?

Laser diffraction is fast, non-destructive, and measures the volumetric geometric size of all droplets and particles in the plume, whether or not they contain drug. Cascade impaction is slower but provides the mass-weighted aerodynamic size distribution of the active ingredient specifically, which is the parameter most relevant to deposition and the one expected by pharmacopoeial monographs and regulators. The two methods are complementary rather than interchangeable.

Which standards govern spray particle size testing?

Compendial methods are given in USP General Chapters <601> and <429>, Ph. Eur. 2.9.18, and the relevant Chinese Pharmacopoeia chapters, while laser diffraction and image analysis methodology follow ISO 13320 and ISO 13322. Regulatory expectations for in vitro data are further defined in FDA and EMA guidance documents on inhalation and nasal products.

Can these tests be outsourced?

Yes. Accredited third-party laboratories equipped with cascade impactors, laser diffraction systems, and validated HPLC assay methods routinely perform spray particle size testing for pharmaceutical manufacturers, generating data suitable for batch release, stability programs, and regulatory submissions.

How many actuations and replicates are required?

Test plans are product-specific, but typical protocols collect pooled actuations for impaction stages, with a minimum of three to ten replicate determinations per batch to demonstrate dose and size distribution uniformity, in line with the sampling requirements of the applicable monograph and validation strategy.